Solriamfetol hydrochloride - Generic Drug Details

What are the generic sources for solriamfetol hydrochloride and what is the scope of freedom to operate?

Solriamfetol hydrochloride is the generic ingredient in one branded drug marketed by Axsome Malta and is included in one NDA. There are forty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Solriamfetol hydrochloride has eighty-eight patent family members in twenty-four countries.

One supplier is listed for this compound.

Summary for solriamfetol hydrochloride

International Patents:	88
US Patents:	42
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	20
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for solriamfetol hydrochloride
DailyMed Link:	solriamfetol hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for solriamfetol hydrochloride

Constraining patent/regulatory exclusivity:

10,195,151

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for solriamfetol hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Hospital, Montpellier	PHASE2
Duke University	PHASE2
National Multiple Sclerosis Society	Phase 2

See all solriamfetol hydrochloride clinical trials

Pharmacology for solriamfetol hydrochloride

Drug Class	Dopamine and Norepinephrine Reuptake Inhibitor
Mechanism of Action	Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for solriamfetol hydrochloride

N06BA	Centrally acting sympathomimetics
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for SOLRIAMFETOL HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SUNOSI	Tablets	solriamfetol hydrochloride	75 mg and 150 mg	211230	6	2023-06-20

US Patents and Regulatory Information for solriamfetol hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Axsome Malta	SUNOSI	solriamfetol hydrochloride	TABLET;ORAL	211230-002	Jun 17, 2019		RX	Yes	Yes	11,986,455
Axsome Malta	SUNOSI	solriamfetol hydrochloride	TABLET;ORAL	211230-002	Jun 17, 2019		RX	Yes	Yes	11,969,404
Axsome Malta	SUNOSI	solriamfetol hydrochloride	TABLET;ORAL	211230-001	Jun 17, 2019		RX	Yes	No	12,036,194

International Patents for solriamfetol hydrochloride

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009112459
New Zealand	751438	Formulations of (r)-2-amino-3-phenylpropyl carbamate
China	101217949	Treatment of sleep-wake disorders

Supplementary Protection Certificates for solriamfetol hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1890684	SPC/GB20/017	United Kingdom		PRODUCT NAME: SOLRIAMFETOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY A HYDROCHLORIDE SALT THEREOF; REGISTERED: UK EU/1/19/1408 (NI) 20200120; UK PLGB 31626/0003 20200120; UK PLGB 31626/0002 20200120
1890684	132020000000040	Italy		PRODUCT NAME: SOLRIAMFETOL O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, PREFERIBILMENTE UN SUO SALE CLORIDRATO(SUNOSI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1408, 20200120
1890684	CA 2020 00016	Denmark		PRODUCT NAME: SOLRIAMFETOL ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, FORTRINSVIST ET HYDROCHLORIDSALT DERAF; REG. NO/DATE: EU/1/19/1408 20200120

Market Dynamics and Financial Trajectory for Solriamfetol Hydrochloride

Last updated: July 30, 2025

---

Introduction

Solriamfetol hydrochloride, marketed under the brand name Sunosi, is a novel pharmacological agent developed for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy and obstructive sleep apnea (OSA). As a dopamine and norepinephrine reuptake inhibitor, solriamfetol represents a distinctive addition to the therapeutics landscape targeting sleep disorders. Its market prospects are shaped by evolving clinical demands, regulatory pathways, competitive forces, and health policy trends. This analysis offers a comprehensive review of the current market dynamics and financial trajectories associated with solriamfetol, emphasizing factors influencing its commercial success.

---

Market Overview and Clinical Context

The sleep disorder therapeutics market is expanding, driven by increasing recognition of sleep disorders’ prevalence and their association with comorbidities such as cardiovascular disease and cognitive impairment. According to the American Academy of Sleep Medicine, approximately 25 million adults suffer from OSA in the U.S., with narcolepsy impacting an estimated 1 in 200,000 individuals.[1] The unmet need for effective EDS treatments has created a receptive market environment.

Solriamfetol finds its niche within this context. The drug’s mechanism as a dual dopamine and norepinephrine reuptake inhibitor positions it uniquely among existing therapies like modafinil, armodafinil, and sodium oxybate. Its approval by the U.S. Food and Drug Administration (FDA) in 2019 marked a significant milestone, opening avenues for market penetration.

---

Factors Driving Market Dynamics

Regulatory Approvals and Market Access

Regulatory endorsement is pivotal; the FDA’s approval of solriamfetol was based on its demonstrated efficacy and safety profile in clinical trials. The medication’s approval for both narcolepsy and OSA fills a therapeutic gap and provides a dual-use indication, broadening its potential patient base. The European Medicines Agency (EMA) has also been attentive to sleep disorder treatments, although approval timelines for solriamfetol in Europe are ongoing, influencing market accessibility.

Market penetration is further influenced by the drug's labeling and reimbursement conditions. In the U.S., reimbursement strategies by payers and PBMs significantly affect prescription patterns. Early collaborations with insurers facilitate rapid adoption and dispensation.

Competitive Landscape

Solriamfetol’s primary competitors include modafinil, armodafinil, and sodium oxybate, with each addressing similar patient populations. However, solriamfetol distinguishes itself through a different mechanism, potentially offering superior wake-promoting effects with a favorable longer-duration profile. Nonetheless, incumbent drugs benefit from established prescribing habits and extensive evidence bases, requiring solriamfetol to invest heavily in post-marketing studies and clinician education.

Emerging competitors, including other novel wake-promoting agents and behavioral interventions, could influence the market share trajectory. The advent of generic formulations of older drugs tends to exert downward pressure on pricing and profitability for newer entrants.

Pharmacoeconomic and Reimbursement Dynamics

Cost-effectiveness analyses and reimbursement policies are central to solriamfetol’s financial trajectory. Health technology assessments (HTAs) in key markets weigh its cost-benefit ratio relative to existing drugs. High drug acquisition costs may be mitigated by demonstrated improvements in quality of life and productivity, prompting payers to include solriamfetol in coverage plans.

Patient Population and Epidemiological Trends

The rising prevalence of sleep apnea, linked to increasing obesity rates, enlarges the potential market. Additionally, greater awareness and improved diagnostic rates expand the diagnosed population. However, adherence issues, including side effects and dosing regimens, impact real-world utilization.

---

Financial Trajectory and Revenue Projections

Market Penetration and Sales Forecasts

Analysts estimate that solriamfetol could achieve peak global sales of approximately $400–600 million within 5 years of launch, contingent on market expansion and payer acceptance.[2] Initial sales are projected to emanate primarily from the U.S. owing to its early approval, with subsequent growth in Europe and Asia-Pacific driven by regulatory approvals and developed healthcare systems.

Pricing Strategy and Revenue Models

Pricing strategies are often aligned with competitive positioning. Solriamfetol’s price point, approximately $10–15 per pill in the U.S., reflects its novel status but is subject to downward pressure from generics and biosimilar development. Volume-based models and partnerships with large healthcare providers are likely to influence overall revenue flow.

Market Share and Growth Potential

Early post-marketing data suggest a slow but steady uptake, particularly among patients intolerant to or insufficiently managed by first-generation therapies. Sustained growth depends on expanding indications, including potential off-label uses and combo therapies.

Investment in R&D and Pipeline Development

R&D investments for solriamfetol include exploring additional indications like ADHD or shift-work disorder, which could significantly bolster its market size. Such pipeline progress could translate into substantial financial uplifts if clinical trials yield positive outcomes.

---

Market Challenges and Risks

Despite promising prospects, multiple challenges threaten financial forecasts. These include:

• Regulatory Delays: Any delays or safety concerns could hamper market entry or expansion.
• Pricing Pressures: Payer pushback on drug costs may restrict access.
• Competitive Dynamics: Rapid emergence of new therapies or generics could erode market share.
• Off-Label Use: Uncontrolled off-label prescribing could complicate clinical management and reimbursement.

---

Strategic Outlook

Manufacturers should focus on post-marketing surveillance to establish long-term safety, invest in real-world evidence generation, and engage in targeted marketing campaigns aimed at clinicians and payers. Strategic collaborations with sleep disorder clinics and insurance providers will be essential for fostering rapid adoption and securing sustainable revenues. Expanding indications and geographic footprints are critical growth avenues.

---

Key Takeaways

• Market potential for solriamfetol is substantial, driven by increasing diagnosis rates of sleep disorders and unmet clinical needs.
• Regulatory approvals in key markets have established a solid foundation, but ongoing approvals are crucial for global expansion.
• Competitive positioning hinges on demonstrating superior efficacy and tolerability over existing therapies, complemented by strategic marketing.
• Pricing and reimbursement strategies will significantly influence revenue trajectories, with cost-effectiveness playing a decisive role.
• Long-term profitability requires pipeline expansion, including exploring new therapeutic indications and geographic markets.

---

Frequently Asked Questions

1. What are the main therapeutic advantages of solriamfetol over existing wake-promoting agents?
Solriamfetol offers a dual mechanism as a dopamine and norepinephrine reuptake inhibitor, providing longer-lasting wakefulness with fewer cognitive side effects compared to traditional agents like modafinil. Its rapid onset and favorable tolerability profile further differentiate it.

2. How does regulatory approval in different regions impact solriamfetol’s market potential?
Early approval in the U.S. positions solriamfetol as a front-runner, but delayed or pending approvals in Europe and Asia may limit immediate market penetration. Regional regulatory pathways often influence launch timelines and payer acceptance.

3. What are the primary obstacles to maximizing solriamfetol’s market share?
Key challenges include competitive saturation, pricing pressures, payer reimbursement hurdles, and clinician familiarity with existing therapies. Ensuring data-driven evidence to justify cost-effectiveness is vital.

4. How could off-label uses influence the financial trajectory of solriamfetol?
Potential off-label indications such as ADHD or shift work disorder could broaden its market base but also pose regulatory and safety considerations, impacting pricing and reimbursement negotiations.

5. What is the outlook for solriamfetol’s long-term revenue growth?
If patent protections hold, indications expand, and marketing efforts succeed, solriamfetol could sustain robust growth, especially in markets with high sleep disorder prevalence. Pipelines exploring additional indications could further enhance revenue potential.

---

References

1. American Academy of Sleep Medicine. Sleep Disorders Overview. 2022.
2. MarketResearch.com. Global Wake-Promoting Agents Market Forecast. 2022.